Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome

Ruxolitinib, a JAK1/2 Inhibitor, Ameliorates Cytokine Storm in Experimental Models of Hyperinflammation Syndrome

Hyperinflammatory syndromes comprise a heterogeneous group of disorders characterized by severe inflammation, multiple organ dysfunction, and potentially death. In response to antigenic stimulus (e.g., SARS-CoV-2 infection), overactivated CD8+ T-cells and macrophages produce high levels of proinflam...

Full description

Bibliographic Details
Main Authors: Eduardo Huarte, Michael T. Peel, Katherine Verbist, Brittany L. Fay, Rachel Bassett, Sabrin Albeituni, Kim E. Nichols, Paul A. Smith
Format: Article
Language:English
Published: Frontiers Media S.A. 2021-04-01
Series:Frontiers in Pharmacology
Subjects:
hyperinflammatory syndromes
cytokine release syndrome
cytokine storm syndrome
hemophagocytic lymphohistiocytosis
JAK inhibition
Online Access:https://www.frontiersin.org/articles/10.3389/fphar.2021.650295/full

Internet

https://www.frontiersin.org/articles/10.3389/fphar.2021.650295/full

Similar Items